AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17506781
Drug: Melatonin 10
RxNorm normalized name: melatonin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 10 mg at night
Trial: 7767514
Drug: ICI 204,219
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 204,219 20 mg
Trial: 7767514
Drug: ICI 204,219
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 204,219 10 mg
Trial: 2082945
Drug: Nitroprusside infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroprusside infusion (n = 10)
Trial: 2082945
Drug: Labetalol bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol bolus injections of 10 mg every 10 min (n = 10)
Trial: 30635141
Drug: Enteral bovine
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteral bovine lactoferrin (150 mg/kg per day; maximum 300 mg/day)
Trial: 30635141
Drug: Sucrose (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (same dose as lactoferrin)
Trial: 19400488
Drug: Intraoperative ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative ketamine infusion combined with spinal anaesthesia
Trial: 10077414
Drug: All drugs
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All drugs (when baseline heart rate ≤ 65 beats/min)
Trial: 7536623
Drug: GAGPS (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAGPS (25 mg, 0.5 ml)
Trial: 2044393
Drug: Ketorolac 30
RxNorm normalized name: ketorolac 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 30 mg intramuscularly up to 4-times a day
Trial: 2044393
Drug: Buprenorphine 0.3
RxNorm normalized name: buprenorphine 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 0.3 mg intramuscularly up to 4-times a day
Trial: 17633370
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine for supporting healthy energy and strengthening Pi, additional to chemotherapy
Trial: 16000607
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (cisplatin-based)
Trial: 15326194
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (single-agent UFT)
Trial: 12399205
Drug: Regular-dose regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular-dose regimen (5 micro g)
Trial: 12399205
Drug: Reduced-dose regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-dose regimen (2.5 micro g)
Trial: 11251757
Drug: Medication grid
RxNorm normalized name: MINERAL OIL 100 g in 100 mL TOPICAL LIQUID [THE GRID]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication grid intervention
Trial: 2974428
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA, 100 mg a day)
Trial: 1426844
Drug: Gd‐DTPA solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gd‐DTPA solution administered per os or per rectum at a concentration of 1 mmol/L
Trial: 1426844
Drug: Gd‐DTPA solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gd‐DTPA solution
Trial: 71447
Drug: Leucocyte-migration-inhibition tests
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucocyte-migration-inhibition tests (L.M.T.) against breast-cancer antigen
Trial: 30353262
Drug: Subanesthetic ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subanesthetic ketamine infusion (0.5 mg/kg over 40 min)
Trial: 30669411
Drug: Wheat Albumin
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat Albumin (WA) 1.5 g
Trial: 30173449
Drug: № I
RxNorm normalized name: Acetylsalicylic acid
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: № I Empirical Prescription for Chronic Prostatitis (1 dose per day for 8 weeks)
Trial: 30173449
Drug: Saw palmetto
RxNorm normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saw palmetto extract (160 mg bid for 8 weeks)
Trial: 2112187
Drug: G‐ORS +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐ORS + RF
Trial: 2112187
Drug: G‐ORS +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐ORS + rice
Trial: 2112187
Drug: G‐ORS +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐ORS + SF
Trial: 465279
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with atenolol and adrenaline
Trial: 30590556
Drug: Drugs with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs with enduring benefits
Trial: 31550810
Drug: Tailored quadruple
RxNorm normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored quadruple therapy based on clarithromycin sensitivity
Trial: 31550810
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving clarithromycin quadruple therapy (PPI, amoxicillin, clarithromycin, bismuth)
Trial: 28755406
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg apple polyphenols for 8 weeks
Trial: 23557482
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention consisting of up to six face-to-face counseling sessions with a trained practice nurse, followed by three-monthly sessions by phone.
Trial: 21538030
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg daily for 8 weeks
Trial: 17328057
Drug: Onercept 100
RxNorm normalized name: Onercept
DrugBank: Onercept (DB06495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onercept 100 mg
Trial: 15316583
Drug: Lactobacillus casei
RxNorm normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus casei fermented milk (108 ‐ 1010/g), 3 cups per day for 8 weeks
Trial: 7612535
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 g four times daily on days 1 to 4 for two cycles)
Trial: 7612535
Drug: Norethisterone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethisterone (5 mg twice a day on days 19 and 26 for two cycles)
Trial: 2653386
Drug: L-DOPA and
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-DOPA and 5 HTP in small doses
Trial: 29549588
Drug: Adapalene 0.3%/Benzoyl
RxNorm normalized name: ADAPALENE 0.3%/BENZOYL PEROXIDE 2.5% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel (A0.3/BPO2.5)
Trial: 27028749
Drug: Umeclidinium/Vilanterol (UMEC/VI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg
Trial: 27028749
Drug: Tiotropium (TIO)
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (TIO) 18 mcg + Indacaterol (IND) 150 mcg
Trial: 27028749
Drug: Tiotropinium (TIO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropinium (TIO) 18 mcg + Indacaterol (IND) 150 mcg
Trial: 24674732
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of Evicel (fibrin sealant)
Trial: 22331237
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (concomitant NP and Rh-endostatin)
Trial: 22331237
Drug: Rh-endostatin combined
RxNorm normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rh-endostatin combined with chemotherapy
Trial: 16381266
Drug: Bupivacaine (0.15%;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (0.15%; 15 mg) + Fentanyl (0.0002%; 2 microg/ml) + Epinephrine (1.7 microg/ml; 1:600,000)
Trial: 16381266
Drug: Bupivacaine (0.15%;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (0.15%; 15 mg) + Fentanyl (0.0002%; 2 microg/ml)
Trial: 8561257
Drug: Chloroquine (CQ)
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine (CQ) 300 mg weekly
Trial: 2539655
Drug: Etoposide 300
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide 300 mg/m2 for two days
Trial: 2539655
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vincristine 1 mg/m2, doxorubicin 50 mg/m2, and cyclophosphamide 1000 mg/m2 (VAC)
Trial: 2539655
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (VAC)
Trial: 71973
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg flurbiprofen daily for 2 weeks
Trial: 30745014
Drug: Furosemide (in-hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (in-hospital dose)
Trial: 31290727
Drug: PD-L1 monoclonal
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PD-L1 monoclonal antibody-conjugated miR-130a/oxaliplatin-loaded immunoliposomes (PD-miOXNP)
Trial: 23011843
Drug: Bupivacaine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (300 mL of 0.5% bupivacaine)
Trial: 23011843
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (300 mL of 0.9% normal saline solution)
Trial: 18081859
Drug: Enamel matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enamel matrix protein derivative (EMD) + low-level laser therapy (LLLT)
Trial: 3110307
Drug: Immune serum
RxNorm normalized name: IMMUNE SERUMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune serum gamma globulin (ISG) 5 or 10 ml
Trial: 3110307
Drug: Immune serum
RxNorm normalized name: IMMUNE SERUMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune serum gamma globulin (ISG) 2 ml
Trial: 15924594
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg once daily (continuous)
Trial: 15924594
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg twice-daily (continuous)
Trial: 15924594
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg once daily (during the 4-week symptom control phase)
Trial: 10650568
Drug: Sucralfate (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (2 g/tid p.o. before meals)
Trial: 1967882
Drug: 1% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% hydrogen peroxide in a stabilized lipid cream applied for 2 min before UVA exposure
Trial: 6160324
Drug: Intravenous pindolol
RxNorm normalized name: Pindolol
DrugBank: Pindolol (DB00960)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pindolol (0.4 mg)
Trial: 6160324
Drug: Oral pindolol
RxNorm normalized name: Pindolol
DrugBank: Pindolol (DB00960)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral pindolol (5 mg, t.i.d.)
Trial: 30680547
Drug: Vitamin B12-fortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12-fortified toothpaste (100 µg cyanocobalamin/g)
Trial: 23318812
Drug: Bupivacaine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (30 ml bolus at 2.5 mg/ml followed by continuous infusion at 5 ml/h for 48 hours)
Trial: 23318812
Drug: Placebo (isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (isotonic saline, same administration as bupivacaine)
Trial: 21111685
Drug: Prednisolone 20
RxNorm normalized name: prednisolone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 20 mg daily for 2 weeks followed by 10 mg daily for 2 weeks (n = 39)
Trial: 19505986
Drug: Long-acting β-agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting β-agonist (LABA) with mandatory inhaled corticosteroid (ICS) therapy
Trial: 16760520
Drug: Rifaximin 200
RxNorm normalized name: rifAXIMin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 200 mg three times a day
Trial: 16760520
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg two times a day
Trial: 9163658
Drug: Sparfloxacin (SPX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin (SPX), 400 mg
Trial: 9163658
Drug: Ciprofloxacin (CPX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (CPX), 500 mg
Trial: 8142159
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (96 mg IV bolus, followed by 96 mg orally for 3 days, then tapered over 10 days)
Trial: 8142159
Drug: No dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: No dexamethasone therapy (control group)
Trial: 3061316
Drug: IgE and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgE and IgG4 antibodies
Trial: 26237806
Drug: Herbal- and
RxNorm normalized name: HERBAL MISCELLANEOUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal- and peloidotherapy as a combination treatment
Trial: 26237806
Drug: Upgraded combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upgraded combination scheme for the treatment of chronic cystitis
Trial: 23011683
Drug: Whole body
RxNorm normalized name: MaxiVision Whole Body Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole body vibration (WBV) therapy, 20 min/day, 5 days/week for 12 months
Trial: 18602725
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of 10 million IU of IFNalpha
Trial: 16809727
Drug: Trastuzumab added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab added concurrently, sequentially, or not at all as adjuvant therapy
Trial: 15323468
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of surgical intervention and radiotherapy
Trial: 8646692
Drug: Treatment variables
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment variables (not specified)
Trial: 6088368
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg cimetidine three times a day and 400 mg at night
Trial: 30039902
Drug: EPG therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPG therapy
Trial: 30039902
Drug: EPG-informed conventional
RxNorm normalized name: dyphylline / ephedrine hydrochloride / guaifenesin / phenobarbital Oral Solution [Lufyllin-EPG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPG-informed conventional therapy
Trial: 30332430
Drug: 150 min/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 min/week of aerobic exercise (low-dose) for six months
Trial: 30332430
Drug: 300 min/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 min/week of aerobic exercise (high-dose) for six months
Trial: 27258504
Drug: Ticagrelor loading
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor loading dose of 360 mg
Trial: 27258504
Drug: Ticagrelor loading
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor loading dose of 180 mg (conventional)
Trial: 21872485
Drug: Triterpene ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triterpene ointment (OG-S10) applied at 100 mg/cm² for 14 days
Trial: 21872485
Drug: Triterpene ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triterpene ointment (OG-S10)
Trial: 19932542
Drug: Adalimumab, 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab, 24 mg/m², every 14 days for 16 weeks (total, 9 doses)
Trial: 15909266
Drug: Artesunate-clindamycin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate-clindamycin (2 mg/kg artesunate and 7 mg/kg clindamycin per dose, twice daily for 3 days)
Trial: 15909266
Drug: Quinine-clindamycin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine-clindamycin (15 mg/kg quinine and 7 mg/kg clindamycin per dose, twice daily for 3 days)
Trial: 9578170
Drug: Ceftazidime 320
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime 320 mg/kg/day
Trial: 9578170
Drug: Ceftazidime 150
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime 150 mg/kg/day
Trial: 28338849
Drug: lifestyle Matters
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lifestyle Matters intervention (weekly group sessions over 4 months and one to one sessions)
Trial: 20854334
Drug: CBT4CBT (computerized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT4CBT (computerized cognitive behavioral therapy)
Trial: 25930952
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (methadone maintenance treatment alone)
Trial: 19910808
Drug: 15 degrees
RxNorm normalized name: ALUMINUM SESQUICHLOROHYDRATE 15.2 g in 100 g TOPICAL AEROSOL, SPRAY [Degree]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 degrees C standard refrigerant gel pack (P)
Trial: 1539751
Drug: Chloroquine 600
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine 600 mg/week
Trial: 1539751
Drug: Chloroquine 300
RxNorm normalized name: chloroquine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine 300 mg/week
Trial: 1539751
Drug: Chloroquine 600
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine 600 mg (post-treatment)
Trial: 15967846
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg PO BID
Trial: 15967846
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg PO TID
Trial: 15967846
Drug: Valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80 mg PO BID plus Captopril 50 mg PO TID
Trial: 11900261
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A - 6-month supervised outpatient exercise program (3 weekly sessions of aerobic and strengthening training on non-dialysis days)
Trial: 7428365
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg vaginal suppository of 15-methyl prostaglandin F2 alpha-methyl ester for Group 1 (9-12 weeks pregnant)
Trial: 7428365
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg vaginal suppository of 15-methyl prostaglandin F2 alpha-methyl ester for Group 2 (13-14 weeks pregnant)
Trial: 7428365
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (1 mg and 1.5 mg)
Trial: 30453788
Drug: 12-h acetylcysteine
RxNorm normalized name: Acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-h acetylcysteine regimen (200 mg/kg over 4 h, 50 mg/kg over 8 h)
Trial: 30453788
Drug: 20-h acetylcysteine
RxNorm normalized name: acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20-h acetylcysteine regimen (200 mg/kg over 4 h, 100 mg/kg over 16 h)
Trial: 26887209
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (comprehensive treatment only)
Trial: 23063327
Drug: Memantine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (10 mg/day for the first week, and 20 mg/day for the rest of the trial)
Trial: 21515866
Drug: Conivaptan hydrochloride
RxNorm normalized name: Conivaptan Hydrochloride
DrugBank: Conivaptan (DB00872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conivaptan hydrochloride 20 mg once daily
Trial: 21515866
Drug: Conivaptan hydrochloride
RxNorm normalized name: Conivaptan Hydrochloride
DrugBank: Conivaptan (DB00872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conivaptan hydrochloride 20 mg twice daily
Trial: 29423372
Drug: Strengthened inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strengthened inhalation therapy for asthma
Trial: 26774179
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 mg/d for the first 15 days, 40 mg/d thereafter; n = 69)